Former Medtronic exec joins CSI to push peripheral artery disease therapy
This article was originally published in Clinica
Executive Summary
Cardiovascular Systems (CSI), the developer of the Diamondback 360° orbital peripheral artery disease (PAD) system, has appointed Kevin Kenny to the new role of executive vice-president of sales and marketing. Prior to joining CSI, Mr Kenny spent nearly 10 years at Medtronic's Spine and Biologics division where he held various senior roles including vice-president of US sales and, most recently, executive consultant for special projects. Mr Kenny will apply his 20-plus years' sales experience to help push commercialisation of CSI's latest orbital PAD system, Stealth 360°, which was cleared by the FDA in March. The St Paul, Minnesota firm's PAD systems treat calcified and fibrotic plaque in arterial vessels throughout the leg within a few minutes.